'OLAP' (OLAparib regulatory Post-marketing surveillance)

Trial Identifier: D0817R00010
Sponsor: AstraZeneca
NCTID:: NCT04553926
Start Date: February 2021
Primary Completion Date: December 2024
Study Completion Date: December 2024
Condition: Breast Cancer; Ovarian Cancer; Pancreatic Cancer; Prostate Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
South Korea Busan, South Korea, 49267
South Korea Busan, South Korea, 48108
South Korea Busan, South Korea, 50615
South Korea Busan, South Korea, 47392
South Korea Cheongju, South Korea, 28644
South Korea Daegu, South Korea, 42415
South Korea Daejeon, South Korea, 35365
South Korea Goyang, South Korea, 10408
South Korea Incheon, South Korea, 21565
South Korea Seongnam, South Korea, 13620
South Korea Seoul, South Korea, 06273
South Korea Seoul, South Korea, 05030
South Korea Seoul, South Korea, 04401
South Korea Seoul, South Korea, ,02841
South Korea Seoul, South Korea, 14577
South Korea Seoul, South Korea, 03722
South Korea Uijeongbu, South Korea, 11765
South Korea Yangsan, South Korea, 50612